Idhifa

Leukemia, Myelocytic, Acute
Treatment
1 FDA approval
7 Active Studies for Idhifa

What is Idhifa

EnasidenibThe Generic name of this drug
Treatment SummaryEnasidenib is a medication used to treat adults with relapsed or refractory acute myeloid leukemia (AML). It is specifically used for patients with mutations in the IDH2 gene, which is present in 12-20% of adult AML patients. To determine eligibility for this drug, testing for the presence of the IDH2 mutation is done on blood or bone marrow samples. Enasidenib prevents cell growth by inhibiting the mutant IDH2 enzyme, as well as other enzymes that contribute to abnormal cell differentiation. It was approved by the FDA in 2017 and is now available for use for those who
Idhifais the brand name
image of different drug pills on a surface
Idhifa Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Idhifa
Enasidenib
2017
2

Approved as Treatment by the FDA

Enasidenib, also called Idhifa, is approved by the FDA for 1 uses including Leukemia, Myelocytic, Acute .
Leukemia, Myelocytic, Acute

Effectiveness

How Idhifa Affects PatientsA study involving adults with certain types of leukemia found that taking enasidenib led to a 40.3% response rate, and the drug was associated with cellular growth and maturation. There is no evidence that enasidenib causes problems with the heart's rhythm.
How Idhifa works in the bodyEnasidenib works by inhibiting a certain enzyme found in mitochondria. This enzyme, called IDH2, helps with different processes in the body, including helping the body adapt to low oxygen levels and changing the structure of genes. In some cases, this enzyme can be mutated, which can cause a type of cancer. Enasidenib works by targeting this mutated form of the enzyme, reducing levels of a substance called 2-hydroxyglutarate and promoting proper cell growth.

When to interrupt dosage

The measure of Idhifa is contingent upon the diagnosed state. The dosage is also contingent upon the technique of administration listed in the following table.
Condition
Dosage
Administration
Leukemia, Myelocytic, Acute
, 50.0 mg, 100.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral

Warnings

There are 20 known major drug interactions with Idhifa.
Common Idhifa Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The serum concentration of Abemaciclib can be increased when it is combined with Enasidenib.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be increased when combined with Enasidenib.
Alectinib
Major
The metabolism of Alectinib can be increased when combined with Enasidenib.
Aminophylline
Major
The metabolism of Aminophylline can be increased when combined with Enasidenib.
Astemizole
Major
The metabolism of Astemizole can be increased when combined with Enasidenib.
Idhifa Toxicity & Overdose RiskIn laboratory tests, enasidenib was not found to cause genetic mutations or damage. However, in repeat-dose toxicity studies, enasidenib was found to cause damage to the reproductive systems of both males and females, including reduced sperm count, deterioration of the prostate and seminal vesicles, decreased egg production, and atrophied uterus.
image of a doctor in a lab doing drug, clinical research

Idhifa Novel Uses: Which Conditions Have a Clinical Trial Featuring Idhifa?

71 active studies are investigating the effectiveness of Idhifa in ameliorating Acute Myelocytic Leukemia.
Condition
Clinical Trials
Trial Phases
Leukemia, Myelocytic, Acute
7 Actively Recruiting
Phase 1, Phase 2

Idhifa Reviews: What are patients saying about Idhifa?

4.7Patient Review
10/17/2022
Idhifa for acute myeloid leukemia with IDH2 mutation
I'm keeping my fingers crossed that this winter will be hospital-free! This drug has really been a lifesaver.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about idhifa

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who manufactures IDHIFA?

"The FDA approved Idhifa for Celgene Corporation and the RealTime IDH2 Assay for Abbott Laboratories on August 1, 2017."

Answered by AI

What is IDHIFA used for?

"IDHIFA is a medication that is used to treat people with acute myeloid leukemia who have an isocitrate. The safety and effectiveness of this medication has not been studied in children."

Answered by AI

Is IDHIFA FDA-approved?

"is the date that the U.S. Food and Drug Administration approved enasidenib (IDHIFA, Celgene Corp.) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia who have an isocitrate dehydrogenase-2 (IDH2) mutation."

Answered by AI

How is IDHIFA administered?

"The ideal dosage of IDHIFA is 100 mg taken by mouth once every day with or without food until the sicknessShow progression or intolerable poisonousness. For patients without sickness progression or intolerable poisonousness, treat for a base time of 6 months to allow time for clinical reaction."

Answered by AI

Clinical Trials for Idhifa

Have you considered Idhifa clinical trials? We made a collection of clinical trials featuring Idhifa, we think they might fit your search criteria.